An Open-label, Observational, Long-term Follow-up Study Evaluating the Safety and Efficacy of RGL-193 Putamen Injection in Patients With Primary Parkinson's Disease

NCT07279844 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 6

Last updated 2025-12-12

No results posted yet for this study

Summary

To evaluate the long-term safety of RGL-193 capsid injection in patients with primary Parkinson's disease over 5 years

Conditions

Interventions

OTHER

Observational

Long-term observational

Sponsors & Collaborators

  • Anhui Provincial Hospital

    lead OTHER_GOV

Principal Investigators

  • Chaoshi Niu · The First Affiliated Hospital of University of Science and Technology of China

Eligibility

Min Age
45 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-15
Primary Completion
2029-12-14
Completion
2029-12-14

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07279844 on ClinicalTrials.gov